Ionis Pharmaceuticals Inc. announced Jan. 4 that it has grabbed another big-name partner in Biogen Inc. for its antisense technology, adding to deals it already has with GlaxoSmithKline Inc. and Genzyme Corp. Biogen and Isis have agreed to collaborate on the development of ISIS-SMN, a Phase I compound meant for the treatment of spinal muscular atrophy (SMA).
Under the terms of the agreement, Biogen will pay Isis $29 million upfront as well as $45 million in potential milestones for the option to license the compound after it has reached the proof of concept phase
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?